Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study

被引:8
|
作者
Chou, Yi-Sheng [1 ,2 ]
Wang, Chun-Chieh [3 ]
Hsu, Li-Fei [4 ]
Chuang, Pei-Hung [5 ]
Cheng, Chi-Feng [2 ]
Li, Nai-Hsin [6 ]
Chen, Chu-Chieh [7 ]
Chen, Chien-Liang [8 ]
Lai, Yun-Ju [1 ,7 ,9 ,10 ]
Yen, Yung-Feng [7 ,11 ,12 ,13 ]
机构
[1] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
[2] Taipei City Hosp, Dept Hematol & Oncol, Renai Branch, Taipei, Taiwan
[3] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Puli Branch, Taichung, Taiwan
[4] Natl Taiwan Univ, Coll Publ Hlth, Taipei, Taiwan
[5] Taipei Assoc Hlth & Welf Data Sci, Taipei, Taiwan
[6] Taipei City Hosp, Dept Gen Surg, Renai Branch, Taipei, Taiwan
[7] Natl Taipei Univ Nursing & Hlth Sci, Dept Hlth Care Management, Taipei, Taiwan
[8] Natl Chi Nan Univ, Dept Econ, Nantou, Taiwan
[9] Taichung Vet Gen Hosp, Dept Internal Med, Div Endocrinol & Metab, Puli Branch, 1 Rongguang Rd, Nantou 545, Taiwan
[10] Natl Taiwan Univ Sport, Dept Exercise Hlth Sci, Taichung, Taiwan
[11] Natl Yang Ming Chiao Tung Univ, Inst Publ Hlth, Taipei, Taiwan
[12] Taipei City Hosp, Yangming Branch, Sect Infect Dis, Taipei, Taiwan
[13] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan
来源
CANCER MEDICINE | 2023年 / 12卷 / 05期
关键词
breast neoplasms; cardiovascular diseases; gonadotropin-releasing hormone; heart disease risk factors; myocardial ischemia; ANDROGEN-DEPRIVATION THERAPY; CARDIOVASCULAR-DISEASE; PROSTATE-CANCER; ADIPOSE-TISSUE; SEX-HORMONES; RISK; GNRH; MEN; ASSOCIATION; WOMEN;
D O I
10.1002/cam4.5390
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The risk of ischemic heart disease (IHD) due to the impact of gonadotropin-releasing hormone (GnRH) agonists among female patients with breast cancer remains a controversy. Methods Information from the Registry for Catastrophic Illness, the National Health Insurance Research Database (NHIRD), and the Death Registry Database in Taiwan were analyzed. Female patients with breast cancer were selected from the Registry for Catastrophic Illness from January 1, 2000, to December 31, 2018. All the breast cancer patients were followed until new-onset IHD diagnosis, death, or December 31, 2018. A Kaplan-Meier survival curve was drawn to show the difference between patients treated with and without GnRH agonists. The Cox regression analysis was used to investigate the effects of GnRH agonists and the incidence of IHD. Results A total of 172,850 female patients with breast cancer were recognized with a mean age of 52.6 years. Among them, 6071(3.5%) had received GnRH agonist therapy. Kaplan-Meier survival curves showed a significant difference between patients with and without GnRH therapy (log-rank p < 0.0001). Patients who received GnRH therapy had a significantly decreased risk of developing IHD than those without GnRH therapy (HR = 0.18; 95% CI = 0.14-0.23). After adjusting for age, treatment, and comorbidity, patients who received GnRH therapy still had a significantly lower risk of developing IHD (AHR = 0.5, 95% CI = 0.39-0.64). Conclusion The study showed that the use of GnRH agonists for breast cancer treatment was significantly associated with a reduced risk of IHD. Further research is required to investigate the possible protective effect of GnRH on IHD.
引用
收藏
页码:5536 / 5544
页数:9
相关论文
共 50 条
  • [31] Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy
    Warnock, JK
    Bundren, JC
    Morris, DW
    BIOLOGICAL PSYCHIATRY, 1998, 43 (06) : 464 - 465
  • [32] Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer
    Krongrad, A
    Brady, J
    Rodriguez, RJ
    SOUTHERN MEDICAL JOURNAL, 1997, 90 (04) : 460 - 461
  • [33] Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment
    Elshimy, Ghada
    Raj, Rishi
    Jacob, Aasems
    Correa, Ricardo
    BMJ CASE REPORTS, 2022, 15 (03)
  • [34] Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer
    Massoud, W
    Paparel, P
    Lopez, JG
    Perrin, P
    Daumont, M
    Ruffion, A
    INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (01) : 87 - 88
  • [35] Gonadotropin-releasing hormone agonists for the management of ovarian cysts in menopause breast cancer patients on tamoxifen treatment
    Kourounis, G
    Zervoudis, S
    Michail, G
    Fotopoulos, A
    BREAST JOURNAL, 2005, 11 (05): : 365 - 366
  • [36] Conservative therapy with a gonadotropin-releasing hormone agonist for a uterine arteriovenous malformation in a patient with congenital heart disease
    Katano, Kinue
    Takeda, Yutaka
    Sugiura-Ogasawara, Mayumi
    CLINICAL CASE REPORTS, 2015, 3 (06): : 479 - 482
  • [37] Anti-Mullerian Hormone levels after ovarian protection with gonadotropin-releasing hormone agonist during chemotherapy in breast cancer patients
    Choi, Y. M.
    Shin, J. J.
    Kim, H.
    Lee, K. H.
    Kim, T. Y.
    Han, W.
    Im, S. A.
    HUMAN REPRODUCTION, 2019, 34 : 339 - 339
  • [38] Gonadotropin-Releasing Hormone Agonist for Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer
    Blumenfeld, Zeev
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) : 3310 - 3310
  • [39] Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy
    Kim, Hee Jeong
    Lee, Moo Hyun
    Lee, Jeong Eon
    Park, Seho
    Lee, Eun Sook
    Kang, Yong Joon
    Shin, Hae Na
    Kim, Seung Il
    Lee, Jun Ho
    Im, Seock Ah
    Ahn, Sei Hyun
    Lee, Keun Seok
    Sohn, Joohyuk
    Kim, Seonok
    Nam, Seok Jin
    Han, Wonshik
    CLINICAL BREAST CANCER, 2018, 18 (05) : E1165 - E1172
  • [40] The criteria for optimal down-regulation with gonadotropin-releasing hormone-agonist: a retrospective cohort study
    Zheng, Yu
    Dong, Xiyuan
    Wang, Rui
    Yang, Wei
    Zhang, Hanwang
    Zhu, Guijin
    Ai, Jihui
    GYNECOLOGICAL ENDOCRINOLOGY, 2015, 31 (12) : 959 - 965